Baird initiated coverage of Longboard Pharmaceuticals with an Outperform rating and $36 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Longboard Pharmaceuticals to Reveal Bexicaserin Study Results
- Longboard Pharmaceuticals Embarks on Risky Global Expansion Amid Regulatory Hurdles and Market Instability
- Longboard Pharmaceuticals files automatic mixed securities shelf
- Longboard Pharmaceuticals Shares Key Corporate Presentation
- Longboard Pharmaceuticals reports FY23 EPS ($2.39), consensus ($2.40)